This link has been bookmarked by 1 people . It was first bookmarked on 11 Oct 2009, by Sigalon - The Swedish Frog.
-
Sigalon - The Swedish Frog"This establishes yet another means of efficacy for LDN (low dose naltrexone). It may even be
the case that some of these chronic pain/inflammation syndromes are due
more to the loss dopaminergic tone, which regulates immunity and
neurotransmission. It even suggests LDN might work in Parkinson's or
that CB1 might be deficient in Parkinson's. I'll have more to say when
my articles are finished. "
***********************
Levodopa is the most commonly prescribed drug for Parkinson's disease
(PD). Although levodopa improves PD symptoms in the initial stages of
the disease, its long-term use is limited by the development of side
effects, including abnormal involuntary movements (dyskinesias) and
psychiatric complications. The endocannabinoid system is emerging as an
important modulator of basal ganglia functions and its pharmacologic
manipulation represents a promising therapy to alleviate
levodopa-induced dyskinesias. Rats with 6-OHDA lesions that are
chronically treated with levodopa develop increasingly severe axial,
limb, locomotor and oro-facial abnormal involuntary movements (AIMs).
Administration of the cannabinoid agonist WIN 55,212-2 attenuated
levodopa-induced axial, limb and oral AIMs dose-dependently via a
CB(1)-mediated mechanism, whereas it had no effect on locomotive AIMs.
By contrast, systemic administration of URB597, a potent FAAH inhibitor,
did not affect AIMs scoring despite its ability to increase anandamide
concentration throughout the basal ganglia. Unlike WIN, anandamide can
also bind and activate transient receptor potential vanilloid type-1
(TRPV1) receptors, which have been implicated in the modulation of
dopamine transmission in the basal ganglia. Interestingly, URB597
significantly decreased all AIMs subtypes only if co-administered with
the TRPV1 antagonist capsazepine. Our data indicate that pharmacological
blockade of TRPV1 receptors unmasks the anti-dyskinetic effects of FAAH
inhibitors and that CB(1) and TRPV1 receptors play opposite roles in
levodopa-induced dyskinesias.
PMID: 17
Would you like to comment?
Join Diigo for a free account, or sign in if you are already a member.